Stealth Biotherapeutics Corp Announces Resignation of Mark Bamberger as Chief Scientific Officer
January 07, 2020 at 05:20 pm
On December 31, 2019, Stealth BioTherapeutics Corp.'s Chief Scientific Officer, Mark Bamberger, submitted notice of his resignation from the Company, effective December 31, 2019. The Company's discovery activities will be overseen by Martin Redmon, Ph.D., Vice President of Pharmaceutical Sciences and Technical Operations. In connection with his resignation, Dr. Bamberger entered into a separation agreement with Stealth BioTherapeutics Inc.